1. |
Plosker GL, Lyseng-Williamson KA. Clopidogrel: a review of its use in the prevention of thrombosis. Drugs, 2007, 67(4): 613-646.
|
2. |
Stone GW, Aronow HD. Long-term care after percutaneous coronary intervention: focus on the role of antiplatelet therapy. Mayo Clin Proc, 2006, 81(5): 641-652.
|
3. |
Pfisterer M, Brunner-La Rocca HP, Buser PT, et al. Late clinical events after clopidogrel discontinuation may limit the benefit of drug-eluting stents: an observational study of drug-eluting versus bare-metal stents. J Am Coll Cardiol, 2006, 48(12): 2584-2591.
|
4. |
Eisenstein EL, Anstrom KJ, Kong DF, et al. Clopidogrel use and long-term clinical outcomes after drug-eluting stent implantation. JAMA, 2007, 297(2): 159-168.
|
5. |
Spertus JA, Kettelkamp R, Vance C, et al. Prevalence, predictors, and outcomes of premature discontinuation of thienopyridine therapy after drug-eluting stent placement: results from the PREMIER registry. Circulation, 2006, 113(24): 2803-2809.
|
6. |
Carlsson J, von Wagenheim B, Linder R, et al. Is late stent thrombosis in drug-eluting stents a real clinical issue?A single-center experience and review of the literature. Clin Res Cardiol, 2007, 96(2): 86-93.
|
7. |
Biondi-Zoccai GG, Lotrionte M, Agostoni P, et al. A systematic review and meta-analysis on the hazards of discontinuing or not adhering to aspirin among 50,279 patients at risk for coronary artery disease. Eur Heart J, 2006, 27(22): 2667-2674.
|
8. |
King SB 3rd, Smith SC Jr, Hirshfeld JW Jr, et al. 2007 Focused update of the ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention: a report of the American College of Cardiology/American Heart Association Task Force on Practice guidelines. J Am Coll Cardiol, 2008, 51(2): 172-2 09.
|
9. |
Higgins JPT, Green S, editors. Assessing risk of bias in included studies. Cochrane Handbook for Systematic Reviews of Interventions 5. 0. 0[updated February 2008, Part 2 Chapter 8. In: The Cochrane Library, Issue 3, 2008. Chichester, UK: John Wiley & Sons, Ltd.
|
10. |
The Cochrane Collaboration. Cochrane Handbook for Systematic Reviews of Interventions 4. 2. 6 Updated May 2006.
|
11. |
吴泰相, 刘关键. 隐蔽分组(分配隐藏)和盲法的概念、实施与报告. 中国循证医学杂志, 2007, 7(3): 222-225.
|
12. |
Liu M, Zhang SH. Intention to treat analysis in clinical trials. BMJ (Chinese edition), 2001, 4(4): 223-224.
|
13. |
刘建平. 非随机研究的系统评价. 中国循证医学, 2001, 1(3): 137-139.
|
14. |
Stroup DF, Berlin JA, Morton SC, et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA, 2000, 283(15): 2008-2012.
|
15. |
Mehta SR, Yusuf S, Peters RJ, et al. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet, 2001, 358(9281): 527-533.
|
16. |
Steven R, Steinhubl, Peter B. Early and Sustained Dual Oral Antiplatelet Therapy Following Percutaneous Coronary Intervention. JAMA, 2002, 288(19): 2411-2420.
|
17. |
Park SJ, Park WD, Kim YH. Duration of Dual Antiplatelet Therapy after Implantation of Drug-Eluting Stents. N Engl J Med, 2010, 362: 1374-1382.
|
18. |
Eisenstein EL, Anstrom KJ, Kong DF, et al. Clopidogrel use and long-term clinical outcomes after drug-eluting stent implantation. JAMA, 2007, 297(2): 159-168.
|
19. |
Brar SS, Kim J, Brar SK, et al. Long-Term Outcomes by Clopidogrel Duration and Stent Type in a Diabetic Population With De Novo Coronary Artery Lesions. J Am Coll Cardiol, 2006, 51(23): 2220-2227.
|
20. |
Kimura T, Morimoto T, Nakagawa Y, et al. Implantation Antiplatelet Therapy and Stent Thrombosis After Sirolimus-Eluting Stent implantation. Circulation, 2009, 119(7): 987-995.
|
21. |
Dean J, Yujie Z, Yingxin Z, et al. Prolonged Dual Antiplatelet Therapy Improves Clinical Outcomes in High-risk Patients Implanted with Sirolimus-eluting Stents. Clin Cardiol, 2009, 32(3): 164-168.
|
22. |
Butler MJ, Eccleston D, Clark DJ, et al. The effect of intended duration of clopidogrel use on early and late mortality and major adverse cardiac events in patients with drug-eluting stents. Am Heart J, 2009, 157(5): 899-907.
|
23. |
King SB III, Smith SC Jr, Hirshfeld JW Jr, et al. 2007 Focused update of the ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention: a report of the American College of Cardiology/American Heart Association Task Force on Practice guidelines. J Am Coll Cardiol, 2008, 51: 172-209.
|
24. |
Mauri L, Kereiakes DJ, Normand SL, et al. Rationale and design of the dual antiplatelet therapy study, a prospective, multicenter, randomized, double-blind trial to assess the effectiveness and safety of 12 versus 30 months of dual antiplatelet therapy in subjects undergoing percutaneous coronary intervention with either drug-eluting stent or bare metal stent placement for the treatment of coronary artery lesions. Am Heart J, 2010, 160(6): 1035-1041. e1.
|
25. |
Byrne RA, Schulz S, Mehilli J, et al. Rationale and design of a randomized, double-blind, placebo-controlled trial of 6 versus 12 months clopidogrel therapy after implantation of a drug-eluting stent: The Intracoronary Stenting and Antithrombotic Regimen: Safety And EFficacy of 6 Months Dual Antiplatelet Therapy After Drug-Eluting Stenting (ISAR-SAFE) study. Am Heart J, 2009, 157(4): 620-624. e2.
|
26. |
Valgimigli M, Campo G, Percoco G, et al. Randomized comparison of 6-versus 24-month clopidogrel therapy after balancing anti-intimal hyperplasia stent potency in all-comer patients undergoing percutaneous coronary intervention: Design and rationale for the PROlonging Dual-antiplatelet treatment after Grading stent-induced Intimal hyperplasia study (PRODIGY). Am Heart J, 2010, 160(5): 804-811.
|